Stay informed with our
free newsletters

Hikma launches Ganciclovir for Injection, USP

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Ganciclovir for Injection, USP, 500mg, in the US, through its US affiliate, Hikma Pharmaceuticals USA Inc

Ganciclovir for Injection, USP is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome, and for the prevention of CMV disease in adult transplant recipients at risk for CMV disease. 

According to IQVIA, US sales of Ganciclovir for Injection, USP, 500mg, were approximately $8 million in the 12 months ending April 2021.

Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.

Imaging CRO Market - A Global and Regional Analysis, 2020-2031

Imaging CRO Market - A Global and Regional Analysis, 2020-2031

Focus on Services, Modalities, Applications, Phases, End User, Country Data (11 Countries), and Competitive Landscape - Analysis and Forecast

Download free sample pages

Source: Hikma
Date: Jun 22, 2021


Share this news: